Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971439 | 0.90 | P2RY12 (0.63) | P2RY12HPGDMEN1KMT2ACYP2D6 | |
| SCHEMBL1967090 | 0.89 | P2RY12 (0.64) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1966980 | 0.87 | P2RY12 (0.63) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1969538 | 0.85 | P2RY12 (0.64) | P2RY12MEN1KMT2A | |
| SCHEMBL1971977 | 0.85 | P2RY12 (0.61) | P2RY12MEN1KMT2A | |
| SCHEMBL1967245 | 0.85 | P2RY12 (0.60) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1967363 | 0.84 | P2RY12 (0.65) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1968871 | 0.83 | P2RY12 (0.64) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1973872 | 0.83 | P2RY12 (0.64) | P2RY12HPGDMEN1KMT2A | |
| SCHEMBL1967936 | 0.82 | P2RY12 (0.72) | P2RY12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885HPGD 375/4885MEN1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.